ArticleInvestigational new drugs2021

Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.

Hiroaki Kodama et al.PubMed ↗Publisher ↗

No numbers read from the abstract.